

Diagnosis & staging

39,409

people were
diagnosed with
lung cancer in 2024

36,557 in 2023 & 36,160 in 2022

♀ 51% female

♂ 49% male

74
years
median age at
diagnosis

40%
↑

of patients were diagnosed at
stage 1-2
36% in 2023 & 32% in 2022

41%
↓

of patients presented **with stage 4
lung cancer**
44% in 2023 & 47% in 2022

30%
↓

of patients were diagnosed **after
emergency admission**
32% in 2023 & 33% in 2022

Key



improving from 2023



worsening from 2023



unchanged from 2023

Waiting times in Non-small Cell Lung Cancer (NSCLC)

81
days

Median time from
referral to **surgery** in
NSCLC stage 1-2

83 days in 2023

63
days

Median time from referral
to **SACT** in NSCLC stage
3B-4

66 days in 2023



Treatment allocation

Treatment with curative intent for Non-Small Cell Lung Cancer (NSCLC)

79%
↓

of patients with NSCLC (stage 1-2,
Performance Status (PS) 0-2) received
treatment with curative intent*



*surgery or radical radiotherapy

≥80%
X

Audit standard

80% in 2023

80% in 2022

59%
↓

of patients with NSCLC (stage 3A,
PS 0-2) received treatment with
curative intent**



**surgery, radical radiotherapy or multimodal treatment

N/A


62% in 2023

61% in 2022

Surgery for Non-Small Cell Lung Cancer (NSCLC)

22%
↑

of patients with NSCLC had
surgical treatment for their cancer



Absolute number of surgeries in 2024: 7,878

≥17%
✓

Audit standard

20% in 2023

18% in 2022

Systemic Anti-Cancer Therapy (SACT) for Non-Small Cell Lung Cancer (NSCLC)

63%
↔

of patients with NSCLC (stage 3B
-4, PS 0-1) received SACT



≥70%
X

Audit standard


63% in 2023

63% in 2022

Systemic Anti-Cancer Therapy (SACT) for Small Cell Lung Cancer (SCLC)

71%
↓

of patients with SCLC received
treatment with SACT



Median time from 'decision to treat' to start SACT: 16 days

≥70%
✓

Audit standard

74% in 2023

73% in 2022

Survival outcomes

19,326 patients were diagnosed between 1 January and 30 June 2024. For these patients:

Median survival

372
days



349 days in 2023
281 days in 2022

One year survival

51%
↑

49% in 2023
45% in 2022

Data quality

Completeness of key routine data items

Stage

93%

90%
✓

Audit standard

Performance status

89%

90%
X

Audit standard

Basis of diagnosis

92%

90%
✓

Audit standard

Morphology

64%

75%
X

Audit standard

Lung Clinical Nurse
Specialist at diagnosis

64%

90%
X

Audit standard

Smoking status

46%

90%
X

Audit standard